Company* |
Company* (Country; Symbol) | Type/Product Area |
Terms/Details (Date) |
| | |||
4SC AG* |
ProQinase GmbH* (Germany) |
Research collaboration to identify a new generation of protein kinase inhibitors as the basis for the development of anticancer drugs |
ProQinase will provide disease-relevant protein kinase targets using its integrated technology platform, including cell-based assays and in vivo models; 4SC will apply its virtual high-throughput screening technology, 4Scan, in combination with medicinal chemistry capabilities (4/28) |
|
|
|
|
Abeta GmbH* |
The Genetics Co. AG* (Switzerland) |
Agreement in which Genetics Co. acquired tools and assays to monitor amyloid-beta peptide levels from Abeta |
Genetics Co. also acquired Abeta's diagnostics business and a therapeutic approach targeting the amyloid precursor protein pathway, in a cash and stock transaction (6/16) |
|
|
|
|
Abgenix Inc. |
Microscience Ltd.* (UK) |
Collaboration to discover, develop and commercialize "passive" immunotherapies against certain infectious disease targets using fully human monoclonal antibodies |
Microscience will provide infectious disease target antigens and Abgenix will use its XenoMouse technology to generate fully human antibodies (5/7) |
|
|
|
|
Acacia Research |
Nanomaterials Discovery Corp.* |
Agreement to license Acacia's CombiMatrix division's micro-array platform technology to Nanomaterials |
Nanomaterials will use the technology in developing its own nanomaterial discovery program, while CombiMatrix will share in revenues from the commercialization of any discovered materials and also will receive a license to intellectual property owned by Nanomaterials (6/17) |
|
|
|
|
Actelion Ltd. |
Axovan AG* (Switzerland) |
Two-year research collaboration to optimize and develop molecules identified by Axovan |
Axovan received an undisclosed up-front payment and is due research and development funding as well as potential milestones and royalties (6/17) |
|
|
|
|
Actelion Ltd. |
Discovery Partners International Inc. (DPII) |
Three-year agreement under which Actelion will procure drug discovery capabilities from Discovery Partners |
Specifics of the program were not disclosed (6/3) |
|
|
|
|
Affitech A/S* |
Peregrine Pharmaceuticals Inc. (PPHM) |
Agreement to collaborate on the production of human antibodies for Peregrine's vascular-targeting agent and anti-angiogenesis programs |
Peregrine will provide targets and Affitech will apply its human antibody libraries and discovery and screening technologies to generate a panel of fully human antibodies against the targets (6/18) |
|
|
|
|
Aradigm Corp. |
Weston Medical Group plc (UK; LSE:WMG) |
Agreement in which Aradigm acquired selected assets of Weston Medical Group |
Aradigm paid about $2M in cash for the assets, which included test and production equipment, intellectual property and other assets associated with Weston's Intraject needle-free delivery technology (5/13) |
|
|
|
|
Ardais Corp.* |
Xantos Biomedicine AG* (Germany) |
Agreement in which Xantos will access the Ardais BIGR Library to obtain clinical genomics resources |
Xantos will apply Ardais' tissue-based products and services to validate the clinical relevance of targets in inflammatory and degenerative diseases identified using its XantosScreen technology (5/14) |
|
|
|
|
Argenta Discovery |
Corcept Therapeutics Inc.* |
Multiyear collaboration for the discovery and optimization of a second- generation drug candidate from one of Corcept's psychiatric disorder programs |
Argenta and Corcept scientists will work in an interdisciplinary team to integrate biology and chemistry (5/7) |
|
|
|
|
Ariad |
DiscoveRx |
Nonexclusive worldwide license agreement that grants DiscoveRx the right to commercialize drug discovery assay products covered by Ariad's NF-(kappa) B patents |
DiscoveRx will pay Ariad an upfront license fee and annual license fees, as well as royalties and milestones based on drug discovery product sales (5/9) |
|
|
|
|
Arrow |
Acambis plc (UK; ACAM; LSE:ACM) |
Collaboration to discover attenuated or subunit vaccines that will involve an evaluation by Acambis of Arrow's target discovery technology, Transposon Mediated Differential Hybridization |
Agreement includes an up-front payment, milestones and royalties, and covers the development of a vaccine for a single pathogen (6/9) |
|
|
|
|
ARUP |
InVivoScribe Technologies LLC* |
Sublicense agreement for several U.S. patents from InVivoScribe |
The patents cover PCR-based testing of immunoglobulin and T-cell receptor loci technology required to detect and monitor leukemias, lymphomas and other lymphoroliferative diseases in patient samples (5/7) |
|
|
|
|
Biogen Inc. |
Genentech Inc. (NYSE:DNA) |
Licensing agreement for worldwide patent rights relating to fusion proteins from Genentech |
The nonexclusive licenses will apply to the approved Amevive and other potential products in Biogen's product pipeline; Biogen will pay an undisclosed royalty to Genentech (6/13) |
|
|
|
|
Biogen Inc. |
Genentech Inc. (NYSE:DNA) |
Collaboration to develop BR3, a key target for developing drugs to treat autoimmune and inflammatory disorders associated with abnormal B-lymphocyte activity, such as rheumatoid arthritis and lupus |
The parties will collaborate on development efforts (6/17) |
|
|
|
|
BioRad Laboratories |
Caliper Technologies Corp. (CALP) |
Multiyear agreement to develop and market a micro-fluidics instrument system for worldwide distribution |
Caliper will receive research and development funding from BioRad, as well as royalties on instruments and software and will be the exclusive manufacturer of LabChip devices (6/5) |
|
|
|
|
BioTransplant |
Miltenyi Biotec GmbH* (Germany) |
Agreement for the sale of BioTransplant's Eligix HDM Cell Separation System |
Miltenyi agreed to acquire all intellectual property and physical assets associated with the Eligix business in exchange for an upront payment of $450,000 and royalties of 4% to 10% of future sales (6/5) |
|
|
|
|
British Biotech |
MerLion Pharmaceuticals Pte Ltd.* (Singapore) |
Two-year research agreement to discover and develop new classes of antibacterial ribosomal inhibitors from natural sources |
The collaboration will combine British Biotech's knowledge in ribosomal biology and structure-based drug design, including site-specific assays, crystallography and NMR technology with MerLion's collection of natural product samples, its high-throughput screening capabilities and natural product and medicinal chemistry expertise (5/14) |
|
|
|
|
CePeP AB* |
DGI BioTechnologies Inc.* |
Pilot program in which the parties will conduct a study to delivery Hotspot Ligands that are antagonists to DGI's drug targets across the plasma membrane in animal models using CePeP's cell-penetrating peptide technology as the delivery tool |
The program might result in a formal research and development collaboration between the companies (5/14) |
|
|
|
|
Chromos Molecular Systems Inc. (Canada; TSE:CHR) |
Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT) |
Licensing agreement focused on Chromos' artificial chromosome expression system, known as ACE, which will be used to manufacture antibodies and biologics |
CAT will use the platform to generate cell lines expressing monoclonal antibodies; the company retains the right tomanufacure and sell therapeutic products that emerge from the deal; Chromos gets undisclosed cash up front, along with annual maintenance fees plus potential milestone and royalty payments (5/15) |
|
|
|
|
Curis Inc. |
Genentech Inc. (NYSE:DNA) |
Licensing agreement for Curis' small-molecule and antibody inhibitors of the Hedgehog signaling pathway for use in cancer |
Genentech will pay a license fee of $8.5M and $2M a year for two years; Curis also could earn milestone payments, making the deal worth $240M; Curis also would receive royalties on sales (6/11) |
|
|
|
|
Curis Inc. |
Project A.L.S.* |
Collaboration to evaluate a therapeutic approach for the treatment of amyotrophic lateral sclerosis |
Collaboration will focus on a biological pathway controlled by the Hedgehog protein (6/5) |
|
|
|
|
Debiopharm SA* (Switzerland) |
GenOdyssee SA* (France) |
Collaboration in which GenOdyssee granted Debiopharm the exclusive worldwide license to develop and commercialize a compound in the therapeutic areas of oncology, oncology-associated side effects and virology from the GenOdyssee portfolio |
Debiopharm will fund development of the product, including manufacturing, preclinical and clinical trials up to its registration; GenOdyssee will receive cash up front and a milestone payment, as well as a share of revenues from the licensing out to a commercial partner (6/4) |
|
|
|
|
Devgen NV* |
Genentech Inc. (NYSE:DNA) |
Research agreement in which Devgen employed its C. elegans in vivo-based RNAi technology and its Function Factory tool to propose a role of genes identified by Genentech in specific cellular pathways |
The agreement is designed to enable Genentech to investigate more closely the function of genes in cancer development and to progress those genes toward drug discovery (6/2) |
|
|
|
|
Dharmacon Inc.* |
Exelixis Inc. |
Agreement to develop a short interfering RNA library for about 600 proprietary and publicly available genes for kinases and other drug discovery targets |
The library is being developed using Dharmacon's SMARTselection and SMARTpool technology platform and manufactured using its 2'-ACE RNA-synthesis chemistry; Exelixis and Dharmacon will apply their bioinformatics capabilities to develop the library (6/12) |
|
|
|
|
Egea |
Centocor Inc. (unit of Johnson & Johnson) |
Exclusive research collaboration to develop at least six optimized protein pharmaceutical products |
Egea will work with Centocor to discover protein biomedicines and will use its gene synthesis technology to create candidates for Centocor (5/13) |
|
|
|
|
EpiTan Ltd. |
CollaGenex Pharmaceuticals Inc. (CGPI) |
Agreement to develop a topical formulation for EpiTan's lead drug candidate, Melanotan |
CollaGenex acquired the rights to the drug delivery system, known as Restoraderm technology, from inventor Thomas Skold; EpiTan sublicensed the technology from CollaGenex (5/20) |
|
|
|
|
Evotec OAI AG |
Artesian Therapeutics Inc.* |
Three-year drug discovery service agreement to optimize small-molecule therapeutics for the treatment of congestive heart failure |
Artesian will use Evotec OAI's medicinal chemistry skills for the optimization of biologically active molecules; Artesian also has the option to use Evotec OAI's biology and development chemistry expertise if required (5/15) |
|
|
|
|
Exact Sciences |
Genzyme Genetics (division of Genzyme Corp.; GENZ)
|
A royalty-free, cross-license agreement covering 15 technology patents that might be useful in developing diagnostic products and services |
The companies will jointly develop specific molecular diagnostic tools in the field of hematologic oncology (5/7) |
|
|
|
|
Exiqon A/S* |
Phoenix BioTechnologies Inc.* |
Licensing agreement for Exiqon's Locked Nucleic Acid analogue technology on a nonexclusive basis |
The agreement entitles Phoenix to manufacture and sell LNA oligonucleotides for the genomics research market (5/28**) |
|
|
|
|
Galapagos |
Inpharmatica |
Drug discovery collaboration in which Inpharmatica will use its PharmaCarta chemo-genomics technology platform to determine the druggability of targets selected by Galapagos in its internal disease programs |
Galapagos will provide access to its PhenoSelect adenoviral expression platform for a subset of nuclear receptors belonging to Inpharmatica, which will use the technology in its in-house programs to further validate and prioritize the receptors as targets (4/29) |
|
|
|
|
Galileo |
First Genetic Trust* |
Collaboration to provide pharmacogenomics research capabilities to the pharma ceutical and biotechnology industries |
The collaboration will create a research resource of large-scale clinical networks from Quebec and the U.S. (6/10) |
|
|
|
|
GATC Biotech |
Genovac AG* (Germany) |
Agreement in antibody production |
The companies will jointly offer their complete chain of production, from tissue or DNA to antibody production; they will outsource key steps, such as cloning specific cDNA or providing molecular biology services, to each other (6/4**) |
|
|
|
|
Generex Biotechnology Corp. (Canada; GNBT) |
Antigen Express Inc.* |
Collaboration to develop severe acute respiratory syndrome vaccines using Generex's drug delivery and formulation technology |
Antigen Express will use its li protein suppression and li-Key peptide vaccine-enhancing technologies in the development of SARS vaccines (5/22) |
|
|
|
|
Genetronics Biomedical Corp. (AMEX:GEB) |
Genteric Inc.* |
Exclusive agreement covering joint evaluation of gene expression using electroporation-assisted delivery of DNA to the salivary gland |
Both companies will own data generated by the research collaboration, which could lead to commercial development of multiple gene therapy products (5/22) |
|
|
|
|
Human Genome |
Abgenix Inc. (ABGX) |
License agreement to develop a fully human monoclonal antibody to Abgenix's CCR5 receptor |
The agreement could include milestone payments that go both ways (5/12) |
|
|
|
|
ILEX Oncology |
QuatRx Pharmaceuticals Co.* |
Agreement for QuatRx to in-license two lipid-focused platforms from ILEX |
QuatRx will make an up-front payment and milestone payments to ILEX; the agreement will focus on QRX-401, which has demonstrated an ability to lower LDL cholesterol and lipoprotein (a) in primate models, as well as a twin mechanism that affects two independent risk factors of cardiovascular disease (5/21) |
|
|
|
|
Ingenium |
Oxagen Ltd.* |
Collaboration under which Ingenium will use its INGENO-typing technology platform to develop animal models with defined gene alterations |
The focus will be on genes relating to metabolic diseases that have been located by Oxagen's target- dentification technology (6/5) |
|
|
|
|
Inimex |
Genicon Sciences Corp.* |
Collaboration to discover diagnostics and therapeutics for infectious diseases |
Genicon will provide reagents, instrumentation and software products based on its RLS Technology to support Inimex research (5/8) |
|
|
|
|
Innodia Inc.* |
Neurochem Inc. (Canada; TSE:NRM) |
Licensing agreement giving Innodia rights to diabetes technology from Neurochem |
Further details were not disclosed (5/8) |
|
|
|
|
InterBioScreen |
Princeton BioMolecular Research Inc.* |
Partnership to produce new generations of discovery molecules |
Companies will exploit their core discovery research competencies in small-molecule chemistry, including InterBioScreen's natural and synthetic chemistry, organization and resources and Princeton BioMolecular's U.S.-based molecular and medicinal chemistry research capabilities (4/29) |
|
|
|
|
Intradigm Corp.* |
Sequitur Inc.* |
Agreement to collaborate on the application of RNAi in animal models of disease and in development of RNAi therapeutics |
Sequitur will provide and license its Stealth RNAi technology to Intradigm for a number of therapeutic targets; Intradigm will provide and license its targeted synthetic gene vector in vivo nucleic acid delivery technology to Sequitur for a number of therapeutic targets (6/13) |
|
|
|
|
Isis |
Ercole Biotech Inc.* |
Multiyear collaboration to discover antisense drugs that regulate alternative RNA splicing |
Ercole will receive a license to certain Isis antisense drugs, based on the RNA splice variant research conducted; each company will pay the other for certain preclinical, clinical and commercial achievements, as well as royalties on sales; Ercole also will receive a license to Isis' Bcl-x preclinical antisense drug (5/19) |
|
|
|
|
LION bioscience AG (Germany; LEON) |
Silicon Genetics Inc.* |
Multiyear joint development and marketing collaboration in which the companies will integrate their software technologies, Silicon Genetics' GeneSpring, LION's SRS and LION Target Engine |
The integration will allow the seamless transfer of data between those products to accelerate and improve cross-functional activities within discovery (6/3) |
|
|
|
|
LumiCyte Inc.* |
Ciphergen Biosystems Inc. (CIPH) |
Exclusive agreement giving Ciphergen rights that were granted to Molecular Analytical Systems Inc. under patents licensed from Baylor College of Medicine |
Ciphergen will pay about $3M in cash and issue about 1.25M shares of Ciphergen stock to LumiCyte and will provide royalty payments, based on revenues, of up to $10M over a 10-year period to Molecular Analytical Systems; the agreement was made as part of a lawsuit between Ciphergen and the two other companies (5/30) |
|
|
|
|
Lynx Therapeutics |
Millennium Pharmaceuticals Inc. (MLNM)
|
Agreement to study gene expression in specific blood cell populations |
The agreement will use Lynx's Massively Parallel Signature Sequencing technology in two areas of study, to identify cell specific gene markers for a certain blood cell type, and to evaluate gene expression patterns from RNA in peripheral blood monocytes in response to treatments with specific compounds (5/15) |
|
|
|
|
Medarex Inc. |
Amrad Corp. (Australia; ASX:AML) |
Licensing partnership for the research and development of fully human therapeutic antibodies against interleukin-13 receptor alpha |
Amrad will use Medarex's UltiMAb Human Antibody Development System to generate antibodies to the IL-13 target; Medarex expects to receive license fees and milestone payments, as well as royalties on commercial sales (5/15) |
|
|
|
|
MedImmune |
Micromet AG* (Germany) |
Licensing agreement for North American rights to Micromet's MT103 |
MedImmune will jointly develop a new class of antibody derivatives with Micromet; both parties agreed to create up to six more candidates; MedImmune is responsible for MT103's clinical development, registration and commercialization in North America, and will make milestone payments and royalty payments to Micromet (6/9) |
|
|
|
|
MerLion |
NovImmune SA* (Switzerland) |
Collaboration to discover and develop immunosuppressive and immunomodulating drugs |
NovImmune will contribute its biochemical and cell-based assays for specific regulators of immune response genes as targets for MerLion to screen against its sample collection discoveries will be jointly developed and shared (5/6) |
|
|
|
|
OctoPlus |
CytImmune Sciences Inc.* |
Agreement to develop a treatment for solid cancers |
The parties will jointly develop a safer formulation to deliver more tumor necrosis factor protein to solid tumors, and will evaluate the product in clinical studies (5/22) |
|
|
|
|
Panacea |
Olympus Optical Co. Ltd.* (Japan) |
Agreement for Panacea to develop an array of assays using the MF20 system recently released by Olympus |
Further details were not disclosed (5/7) |
|
|
|
|
Pepscan Systems |
PowderJect Pharmaceuticals plc (UK; LSE:PJP) |
Agreement for Pepscan to license its lead prostate cancer vaccine to PowderJect |
Pepscan will manage the project through Phase I trials, after which PowderJect will be responsible for further clinical testing, regulatory approval and marketing; Pepscan received an up-front fee and is due milestones and royalties (5/13) |
|
|
|
|
Plexxikon Inc.* |
Genentech Inc. (NYSE:DNA) |
Agreement in which Plexxikon will use its Scaffold-Based Drug Discovery platform to develop a series of protein lead compounds against an undisclosed gene target in the protein kinase family |
Plexxikon is scheduled to receive an up-front technology access fee plus research funding; it also could receive milestone payments and royalties (5/20) |
|
|
|
|
Scynexis |
Molecular Engines Laboratories* |
Research collaboration focused on anticancer therapeutics |
Molecular Engines will access compounds produced by the Scynexis automated Medchem Factory and its HEOS software; Molecular Engines will retain intellectual property and exclusive worldwide rights to products in exchange for technology access fees and other compensation for Scynexis technologies and services (6/4) |
|
|
|
|
Tularik Inc. |
Amgen Inc. (AMGN) |
Agreement for an oncology collaboration |
Amgen will buy 21.3% of Tularik, $35M worth of newly issued stock; it also is committing $125M in funding; Amgen will buy another $40M worth of Tularik shares over the next three years, paying Tularik up to $21M per cancer target selected; Amgen keeps exclusive worldwide commercialization rights to products; Tularik retains an option for co-promotion rights in undisclosed indications in the U.S. on a product-by-product basis (5/21) |
|
|
|
|
Valentis Inc. |
Juvaris BioTherapeutics Inc.* |
Nonexclusive licensing agreement for Juvaris to use Valentis' plasmid backbone and cationic lipid-delivery technologies for the development and commercialization of therapeutic vaccine products |
Valentis will receive an up-front cash payment and is eligible for future product development milestones and royalties on sales; Juvaris will be responsible for the development, manufacturing and commercialization of products and will bear all related program expenses (5/22) |
|
|
|
|
Xenogen Corp.* |
Biogen Inc. (BGEN) |
Agreement that will evaluate Xenogen's real-time, in vivo imaging technology in its discovery research programs |
Biogen gained a license to Xenogen's IVIS imaging system and Living Image software package, and will receive access to a limited number of Xenogen's Bioware cells and in vivo models (5/22) |
|
| |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | |||
